Literature DB >> 22017729

Reason for clozapine cessation.

N B Pai1, S C Vella.   

Abstract

OBJECTIVE: Approximately 30% of individuals diagnosed with schizophrenia suffer from treatment-resistant or refractory schizophrenia. The gold standard for treatment of refractory schizophrenia is clozapine. However, a significant number of patients cease clozapine therapy; therefore this study explores patient's motives for cessation.
METHOD: The motives for cessation and duration of clozapine treatment from a retrospective database of 151 patients with schizophrenia or schizo-affective disorder who had ceased clozapine once or more were reviewed, with the motives for cessation coded. The general motives for cessation were non-compliance, own decision, medical, poor response and other. In addition, the medical reasons for cessation were further codified: cardiac complications, neutropenia, fevers, other side effects and pregnancy.
RESULTS: The majority of patients ceased clozapine owing to non-compliance with medical protocols or citing their own decision. Approximately half ceased after a period of 6 months or less. Seventeen per cent of patients ceased owing to medical reasons, with the largest proportions discontinuing treatment because of other side effects or neutropenia.
CONCLUSION: Future research should seek to further investigate why patients decide to be non-compliant and formulate their own decision to cease treatment, as this will facilitate strategies to promote adherence amongst these two groups that are potentially the most amenable to change.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22017729     DOI: 10.1111/j.1600-0447.2011.01776.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  7 in total

Review 1.  Clozapine in Reducing Aggression and Violence in Forensic Populations.

Authors:  Kathleen Patchan; Gopal Vyas; Ann L Hackman; Marie Mackowick; Charles M Richardson; Raymond C Love; Ikwunga Wonodi; MacKenzie A Sayer; Matthew Glassman; Stephanie Feldman; Deanna L Kelly
Journal:  Psychiatr Q       Date:  2018-03

Review 2.  Prevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-Analysis.

Authors:  Ayala Shirazi; Brendon Stubbs; Lucia Gomez; Susan Moore; Fiona Gaughran; Robert J Flanagan; James H MacCabe; John Lally
Journal:  Int J Mol Sci       Date:  2016-06-02       Impact factor: 5.923

3.  Reducing the Risk of Withdrawal Symptoms and Relapse Following Clozapine Discontinuation-Is It Feasible to Develop Evidence-Based Guidelines?

Authors:  Graham Blackman; Ebenezer Oloyede; Mark Horowitz; Robert Harland; David Taylor; James MacCabe; Philip McGuire
Journal:  Schizophr Bull       Date:  2022-01-21       Impact factor: 9.306

4.  Ivabradine, a novel treatment for clozapine-induced sinus tachycardia: a case series.

Authors:  John Lally; Jennifer Brook; Thomas Dixon; Fiona Gaughran; Sukhi Shergill; Narbeh Melikian; James H MacCabe
Journal:  Ther Adv Psychopharmacol       Date:  2014-06

5.  Reasons for discontinuing clozapine: A cohort study of patients commencing treatment.

Authors:  Sophie E Legge; Marian Hamshere; Richard D Hayes; Johnny Downs; Michael C O'Donovan; Michael J Owen; James T R Walters; James H MacCabe
Journal:  Schizophr Res       Date:  2016-05-19       Impact factor: 4.939

6.  Natural Medicines for Psychotic Disorders: A Systematic Review.

Authors:  H J Rogier Hoenders; Agna A Bartels-Velthuis; Nina K Vollbehr; Richard Bruggeman; Henderikus Knegtering; Joop T V M de Jong
Journal:  J Nerv Ment Dis       Date:  2018-02       Impact factor: 2.254

7.  Clozapine- and non-clozapine-associated neutropenia in patients with schizophrenia: a retrospective cohort study.

Authors:  Claas-Frederik Johannsen; Tonny Studsgaard Petersen; Jimmi Nielsen; Anders Jørgensen; Espen Jimenez-Solem; Anders Fink-Jensen
Journal:  Ther Adv Psychopharmacol       Date:  2022-03-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.